A comprehensive review on Non-Alcoholic Fatty Liver Disease (NAFLD): Clinical Advancement and Drug Treatments

Bhumika sahu

doi:10.5281/zenodo.11550341

editor.probsci@gmail.com

Probecell Science

Open Access | E-ISSN: 3049-1584

Abstract View

A comprehensive review on Non-Alcoholic Fatty Liver Disease (NAFLD): Clinical Advancement and Drug Treatments

Author(s): Bhumika sahu

Email(s): bhumikachandel002@gmail.com

Address:

Chhatrapati Shivaji Institute of Pharmacy, Durg, Chhattisgarh - 491001

Published In: Volume - 1, Issue - 1, Year - 2024

DOI: 10.5281/zenodo.11550341

View HTML

View PDF

Please allow Pop-Up for this website to view PDF file.

ABSTRACT:
Hepatic steatosis, fibrosis, cirrhosis, and even hepatocellular cancer can all be part of NAFLD, which also includes less severe forms of fatty liver disease. The global epidemic of nonalcoholic fatty liver disease is mostly attributable to the accumulation of triglycerides and free fatty acids in the liver, a condition exacerbated by obesity and insulin resistance (NAFLD). Metabolic abnormalities or insulin resistance at the disease's physiological core are just two of the many factors that have been hypothesised to have a role in NAFLD development. The risk of death from both liver disease and cardiovascular disease is increased in patients with NAFLD, and NAFLD is quickly becoming the most common reason for a liver transplant, surpassing even liver cancer. Although a liver biopsy is still the gold standard for diagnosis, advances in noninvasive imaging, biochemical, and genetic tests promise to give future clinicians a wealth of new data with which to better understand the disease's pathophysiology and devise more precise treatments. There are already a number of drugs and supplements used for the treatment of NAFLD, but none of them have proven to be the "magic bullet" needed to stop this alarming trend. This review aims to summarise what is currently known regarding the epidemiology, risk factors, diagnosis, pathophysiology, pathologic changes, natural history, and treatment of NAFLD to aid in better understanding the illness and better managing patients with NAFLD.

Keywords:

Cite this article:
Sahu, B. Comprehensive Review on Non-Alcoholic Fatty Liver Disease (NAFLD): Clinical Advancement and Drug Treatments. Prob. Sci. 2024;1(1):1-7.DOI: https://doi.org/10.5281/zenodo.11550341

[1] Cotter TG, Rinella M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology. 2020;158(7):1851-1864.

[2] Younossi ZM, Blissett D, Blissett R, Henry L, Stepanova M, Younossi Y, Racila A, Hunt S, Beckerman R. The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe. Hepatology. 2016.

[3] Gill MG, Majumdar A. Metabolic associated fatty liver disease: Addressing a new era in liver transplantation. World J Hepatol. 2020;12(12):1168-118.

[4] Singh S, Osna NA, Kharbanda KK. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review. World J Gastroenterol. 2017;23(36):6549-6570.

[5] Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol. 2017;9(16):715-732.

[6] Teng YX, Xie S, Guo PP, Deng ZJ, Zhang ZY, Gao W, Zhang WG, Zhong JH. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Current Progresses and Challenges. J Clin Transl Hepatol. 2022;10(5):955-964.

[7] VanWagner LB, Rinella ME. Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease. Curr Hepatol Rep. 2016;15(2):75-85.

[8] Fabbrini E, Sullivan S, Klein S. Obesity and nonalcoholic fatty liver disease: biochemical, metabolic, and clinical implications. Hepatology. 2010;51(2):679-89.

[9] Heyens LJM, Busschots D, Koek GH, Robaeys G, Francque S. Liver Fibrosis in Non-alcoholic Fatty Liver Disease: From Liver Biopsy to Non-invasive Biomarkers in Diagnosis and Treatment. Front Med (Lausanne). 2021;8:615978.

[10] Williams R, Periasamy M. Genetic and Environmental Factors Contributing to Visceral Adiposity in Asian Populations. Endocrinol Metab (Seoul). 2020;35(4):681-695.

[11] Albhaisi S, Chowdhury A, Sanyal AJ. Non-alcoholic fatty liver disease in lean individuals. JHEP Rep. 2019;1(4):329-341

[12] Agbim U, Carr RM, Pickett-Blakely O, Dagogo-Jack S. Ethnic Disparities in Adiposity: Focus on Non-alcoholic Fatty Liver Disease, Visceral, and Generalized Obesity. Curr Obes Rep. 2019;8(3):243-254.

[13] Shakir AK, Suneja U, Short KR, Palle S. Overview of Pediatric Nonalcoholic Fatty Liver Disease: A Guide for General Practitioners. J Okla State Med Assoc. 2018;111(8):806-811.

[14] Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol. 2014;20(31):10851-63.

[15]Nassir F. NAFLD: Mechanisms, Treatments, and Biomarkers. Biomolecules. 2022;12(6):824.

[16] Lonardo A, Nascimbeni F, Maurantonio M, Marrazzo A, Rinaldi L, Adinolfi LE. Nonalcoholic fatty liver disease: Evolving paradigms. World J Gastroenterol. 2017;23(36):6571-6592.

[17] Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: a meta-analysis. Sci Rep. 2019;9(1):11124.

Related Images: